VTRS · 10-Q · 2026Q3

Viatris Inc

Filed 2026-11-05 · Healthcare · View original filing on EDGAR

Everything VTRS's SEC filings said, ranked

Ranked Events

• Other Income (Expense), NetImportance 63 · Surprise 64
  Other expense, net fell by $481.6 million to $18.3 million for the nine months ended September 30, 2026, from $499.9 million in the prior-year period. The primary driver was the absence of the prior-year $499.8 million…
• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  On October 8, 2026, Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The company commenced its offer on October 30, which is…
• Income Tax Rate ChangesImportance 57 · Surprise 64
  For the nine months ended September 30, 2026, Viatris recorded an $84.3 million income tax provision, compared with a $147.2 million benefit in the prior-year period, a $231.5 million change. The current-period…
• Revenue Concentration RiskImportance 55 · Surprise 32
  Viatris’ ten largest products represented approximately 41% of net sales in the third quarter of 2026, compared with 38% in the third quarter of 2025. For the first nine months, the top ten represented approximately…
• Capital Expenditure PlanImportance 54 · Surprise 24
  Viatris reported capital expenditures of approximately $178.4 million for the nine months ended September 30, 2026, primarily for equipment and facilities. For calendar 2026, the company expects capital expenditures of…
• Capital Return ProgramImportance 51 · Surprise 64
  Viatris’ board-authorized share repurchase program permits repurchases of up to $2.0 billion and has no expiration date. In the third quarter of 2026, the company repurchased approximately 8.9 million shares for $150.0…
• Headcount / RestructuringImportance 46 · Surprise 42
  Viatris began implementing restructuring activities following its enterprise-wide strategic review, announced February 26, 2026, to optimize commercial capabilities, enabling functions, R&D, medical affairs, regulatory…
• Nashik Supply DisruptionImportance 46 · Surprise 42
  A February 2026 fire at Viatris’ Nashik, India oral solid dose facility temporarily suspended manufacturing, and subsequent FDA inspection observations led to remediation and further operational disruption.…
• Liquidity and Debt PositionImportance 44 · Surprise 24
  Viatris held $1.79 billion of cash and cash equivalents at September 30, 2026. The company had access to a $3.5 billion revolving facility maturing in September 2029 and a receivables facility of up to $600 million…
• Goodwill Impairment ChargeImportance 42 · Surprise 42
  Viatris recorded a $2.94 billion goodwill impairment charge during the prior-year period in conjunction with its interim impairment test as of March 31, 2025. The charge contributed to the prior-year nine-month GAAP…
• Supply Chain AgreementsImportance 38 · Surprise 24
  Viatris continues to manufacture and supply products for buyers under agreements associated with its divestitures, generally for periods of one to 10 years depending on the geographic market and products involved. Some…
• Accrued Legal and RegulatoryImportance 38 · Surprise 24
  Viatris reported approximately $459 million accrued for legal contingencies as of September 30, 2026, and said it faces disputes, governmental or regulatory inquiries, investigations, proceedings, and litigation in the…
• Operating Cash Flow TrendsImportance 35 · Surprise 22
  Net cash provided by operating activities increased $169.4 million, or approximately 11%, to $1.67 billion for the nine months ended September 30, 2026, from $1.50 billion in the prior-year period. Viatris attributed…
• Acquisitions and DivestituresImportance 34 · Surprise 42
  Viatris completed the sale of its Biocon Biologics equity position on July 14, 2026, receiving pre-tax proceeds of approximately $380 million. The transaction followed the December 2025 agreement under which Biocon…
• Gross Margin DriversImportance 31 · Surprise 32
  Third-quarter 2026 gross profit increased $66.5 million to $1,438.0 million, and gross margin rose to 38% from 36% a year earlier. The company attributed the improvement primarily to lower sales of lower-margin…
• Revenue Performance and MixImportance 31 · Surprise 32
  Third-quarter 2026 total revenues were $3,749.5 million, down $10.4 million from $3,759.9 million a year earlier; first-nine-month revenues rose 4% to $11,023.3 million from $10,596.3 million. Nine-month…
• Greater China GrowthImportance 30 · Surprise 40
  Greater China net sales increased 14% in the third quarter and 19% in the first nine months of 2026 year over year. On a constant-currency basis, growth was 10% and 15%, respectively. Viatris attributed the increase to…
• Strategic Portfolio ReviewImportance 19 · Surprise 6
  Viatris says it continuously evaluates acquisitions of products and companies as part of its future growth strategy and may use cash reserves or incur additional debt to finance them, potentially affecting future…

Revenue by Product (in millions)

Revenue by Geography (in millions)